This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
HAYES, Inc.. Nitric oxide breath analysis for the management of asthma. Lansdale: HAYES, Inc.. Directory Publication. 2016
The measurement of nitric oxide (NO) concentration in expired breath has been introduced as an adjunct to or replacement for established clinical and laboratory assessments of asthma control to guide the management of asthma. Measurement of fractional exhaled nitric oxide (FENO) is a noninvasive diagnostic technique. The NO molecules exhaled in breath can be measured using a handheld electrochemical sensor or a large, stationary chemiluminescence gas analyzer.
Controversy: NO, which is normally produced by the respiratory tract mucosa, is believed to be a powerful mediator involved in airway inflammation. The level of FENO could serve as a surrogate indicator or marker of airway inflammation, providing information to guide changes in asthma medications as the severity of asthma worsens or resolves. Asthma is a complex disease that has many potential contributing factors. Measurement of FENO may not be enough information to guide asthma therapy since it detects only 1 contributing factor. Furthermore, FENO may only be accurate for patients who have certain types of asthma. Relevant Questions: Does measurement of exhaled NO provide information that improves the management of asthma? Is FENO measurement safe? Which patients might be suitable candidates for guidance of asthma therapy based on FENO levels?
Subject indexing assigned by CRD
Asthma; Breath Tests; Disease Management; Humans; Nitric Oxide
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: firstname.lastname@example.org
Date abstract record published